This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (81)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Cardiovascular System  • Surgery  • Surgical Physiology, Other  • Prognosis/ Outcomes  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

The Atherosclerosis Risk in Communities Study

Aaron R. Folsom, MD, MPH; Lloyd E. Chambless, PhD; Christie M. Ballantyne, MD; Josef Coresh, MD, PhD; Gerardo Heiss, MD; Kenneth K. Wu, MD, PhD; Eric Boerwinkle, PhD; Thomas H. Mosley, Jr, PhD; Paul Sorlie, PhD; Guoqing Diao, PhD; A. Richey Sharrett, MD, DrPH

Arch Intern Med. 2006;166:1368-1373.

Background  There has been interest in recent years in whether additional, and in particular novel, risk factors or blood markers, such as C-reactive protein, can enhance existing coronary heart disease (CHD) prediction models.

Methods  Using a series of case-cohort studies, the prospective Atherosclerosis Risk in Communities (ARIC) Study assessed the association of 19 novel risk markers with incident CHD in 15 792 adults followed up since 1987-1989. Novel markers included measures of inflammation, endothelial function, fibrin formation, fibrinolysis, B vitamins, and antibodies to infectious agents. Change in the area under the receiver operating characteristic curve (AUC) was used to assess the additional contribution of novel risk markers to CHD prediction beyond that of traditional risk factors.

Results  The basic risk factor model, which included traditional risk factors (age, race, sex, total and high-density lipoprotein cholesterol levels, systolic blood pressure, antihypertensive medication use, smoking status, and diabetes), predicted CHD well, as evidenced by an AUC of approximately 0.8. The C-reactive protein level did not add significantly to the AUC (increase in AUC of 0.003), and neither did most other novel risk factors. Of the 19 markers studied, lipoprotein-associated phospholipase A₂, vitamin B₆, interleukin 6, and soluble thrombomodulin added the most to the AUC (range, 0.006-0.011).

Conclusions  Our findings suggest that routine measurement of these novel markers is not warranted for risk assessment. On the other hand, our findings reinforce the utility of major, modifiable risk factor assessment to identify individuals at risk for CHD for preventive action.

Author Affiliations: Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis (Drs Folsom); Department of Biostatistics (Drs Chambless and Diao), and Department of Epidemiology, School of Public Health (Dr Heiss), University of North Carolina, Chapel Hill; Department of Medicine, Baylor College of Medicine (Dr Ballantyne), Hemostasis Laboratory, Division of Hematology (Dr Wu), and Human Genetics Center and Institute of Molecular Medicine (Dr Boerwinkle), University of Texas Health Science Center, Houston; Departments of Epidemiology (Drs Coresh and Sharrett) and Biostatistics and Medicine (Dr Coresh), Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Md; Department of Medicine (Geriatrics), University of Mississippi Medical Center, Jackson (Dr Mosley); and National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md (Dr Sorlie).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Predicting Cardiovascular Risk: So What Do We Do Now?
Donald M. Lloyd-Jones and Lu Tian
Arch Intern Med. 2006;166(13):1342-1344.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

C-reactive protein improves risk prediction in patients with acute coronary syndrome, or does it?
Kaski
Eur Heart J 2009;0:ehp435v1-ehp435.
FULL TEXT  

C-Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-analyses for the U.S. Preventive Services Task Force
Buckley et al.
ANN INTERN MED 2009;151:483-495.
ABSTRACT | FULL TEXT  

Emerging Risk Factors for Coronary Heart Disease: A Summary of Systematic Reviews Conducted for the U.S. Preventive Services Task Force
Helfand et al.
ANN INTERN MED 2009;151:496-507.
ABSTRACT | FULL TEXT  

Newer Antiphospholipid Antibodies Predict Adverse Outcomes in Patients With Acute Coronary Syndrome
Greco et al.
Am J Clin Pathol 2009;132:613-620.
ABSTRACT | FULL TEXT  

Urinary Adiponectin Excretion: A Novel Marker for Vascular Damage in Type 2 Diabetes
von Eynatten et al.
Diabetes 2009;58:2093-2099.
ABSTRACT | FULL TEXT  

Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease
Elliott et al.
JAMA 2009;302:37-48.
ABSTRACT | FULL TEXT  

Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community
Melander et al.
JAMA 2009;302:49-57.
ABSTRACT | FULL TEXT  

Biomarkers and Cardiovascular Disease: Determining Causality and Quantifying Contribution to Risk Assessment
Shah and de Lemos
JAMA 2009;302:92-93.
FULL TEXT  

The Report Card on Growth Differentiation Factor 15: Consistent Marks But Not Yet Ready for Promotion
Rohatgi and de Lemos
Circ Cardiovasc Genet 2009;2:209-211.
FULL TEXT  

Impact of socioeconomic, behavioral and clinical risk factors on mortality
Rask et al.
J Public Health (Oxf) 2009;31:231-238.
ABSTRACT | FULL TEXT  

Impact of Adding a Single Allele in the 9p21 Locus to Traditional Risk Factors on Reclassification of Coronary Heart Disease Risk and Implications for Lipid-Modifying Therapy in the Atherosclerosis Risk in Communities Study
Brautbar et al.
Circ Cardiovasc Genet 2009;2:279-285.
ABSTRACT | FULL TEXT  

Do inflammatory biomarkers add to the discrimination of cardiovascular disease after allowing for social deprivation? Results from a 10 year cohort study in Glasgow, Scotland
Woodward et al.
Eur Heart J 2009;0:ehp115v1-ehp115.
ABSTRACT | FULL TEXT  

C-Reactive Protein and Coronary Heart Disease: Predictive Test or Therapeutic Target?
Hingorani et al.
Clin. Chem. 2009;55:239-255.
ABSTRACT | FULL TEXT  

Association Between C-Reactive Protein Genotype, Circulating Levels, and Aortic Pulse Wave Velocity
Schumacher et al.
Hypertension 2009;53:150-157.
ABSTRACT | FULL TEXT  

Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study
de Ruijter et al.
BMJ 2009;338:a3083-a3083.
ABSTRACT | FULL TEXT  

Evaluating cardiovascular risk assessment for asymptomatic people
Scott
BMJ 2009;338:a2844-a2844.
FULL TEXT  

Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline
Rosenzweig et al.
J. Clin. Endocrinol. Metab. 2008;93:3671-3689.
ABSTRACT | FULL TEXT  

Importance of a Patient's Personal Health History on Assessments of Future Risk of Coronary Heart Disease
Mainous et al.
J Am Board Fam Med 2008;21:408-413.
ABSTRACT | FULL TEXT  

Review: Endothelial progenitor cells: markers of vascular reparative capacity
Povsic and Goldschmidt-Clermont
Ther Adv Cardiovasc Dis 2008;2:199-213.
ABSTRACT  

Effects of Socioeconomic Position on Inflammatory and Hemostatic Markers: A Life-Course Analysis in the 1958 British Birth Cohort
Tabassum et al.
Am J Epidemiol 2008;167:1332-1341.
ABSTRACT | FULL TEXT  

New cardiovascular risk determinants do exist and are clinically useful
Levinson
Eur Heart J 2008;29:1335-1335.
FULL TEXT  

Cardiovascular Outcomes in the Outpatient Kidney Transplant Clinic: The Framingham Risk Score Revisited
Kiberd and Panek
CJASN 2008;3:822-828.
ABSTRACT | FULL TEXT  

Why traumatic leg amputees are at increased risk for cardiovascular diseases
Naschitz and Lenger
QJM 2008;101:251-259.
ABSTRACT | FULL TEXT  

Comparison of Risk Stratification Schemes to Predict Thromboembolism in People With Nonvalvular Atrial Fibrillation
Fang et al.
J Am Coll Cardiol 2008;51:810-815.
ABSTRACT | FULL TEXT  

New cardiovascular risk determinants do exist and are clinically useful
Smulders et al.
Eur Heart J 2008;29:436-440.
ABSTRACT | FULL TEXT  

New cardiovascular risk factors exist, but are they clinically useful?
Wang
Eur Heart J 2008;29:441-444.
ABSTRACT | FULL TEXT  

Myeloperoxidase, but not C-reactive protein, predicts cardiovascular risk in peripheral arterial disease
Brevetti et al.
Eur Heart J 2008;29:224-230.
ABSTRACT | FULL TEXT  

Polycystic Ovarian Syndrome, Biomarkers, and Metformin: Research, Risk, and Reality
Sattar and Nelson
J. Clin. Endocrinol. Metab. 2008;93:34-36.
FULL TEXT  

Risk assessment in the patient with established peripheral arterial disease
Haugen et al.
Vasc Med 2007;12:343-350.
ABSTRACT  

Rate of Change and Instability in Body Mass Index, Insulin Resistance, and Lipid Metabolism as Predictors of Atherosclerotic Vascular Disease
Christen et al.
J. Clin. Endocrinol. Metab. 2007;92:3780-3787.
ABSTRACT | FULL TEXT  

Cardiovascular Biomarkers: Added Value With an Integrated Approach?
Koenig
Circulation 2007;116:3-5.
FULL TEXT  

Association of Carotid Artery Intima-Media Thickness, Plaques, and C-Reactive Protein With Future Cardiovascular Disease and All-Cause Mortality: The Cardiovascular Health Study
Cao et al.
Circulation 2007;116:32-38.
ABSTRACT | FULL TEXT  

Prediction of Coronary Heart Disease Risk using a Genetic Risk Score: The Atherosclerosis Risk in Communities Study
Morrison et al.
Am J Epidemiol 2007;166:28-35.
ABSTRACT | FULL TEXT  

C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk: Moving an Inflammatory Hypothesis Toward Consensus
Ridker
J Am Coll Cardiol 2007;49:2129-2138.
ABSTRACT | FULL TEXT  

The Prognostic Accuracy of Coronary Calcification
Guerci
J Am Coll Cardiol 2007;49:1871-1873.
FULL TEXT  

The Year in Atherothrombosis
Sanz et al.
J Am Coll Cardiol 2007;49:1740-1749.
FULL TEXT  

C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)
Sattar et al.
Circulation 2007;115:981-989.
ABSTRACT | FULL TEXT  

Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction
Cook
Circulation 2007;115:928-935.
ABSTRACT | FULL TEXT  

Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in Women: The Reynolds Risk Score
Ridker et al.
JAMA 2007;297:611-619.
ABSTRACT | FULL TEXT  

Lipoprotein-Associated Phospholipase A2 and Risk Stratification for Cardiovascular Disease: Not Ready for 'Prime Time'
Steinberg and Mayer
Mayo Clin Proc. 2007;82:155-157.
FULL TEXT  

Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death
Wang et al.
NEJM 2006;355:2631-2639.
ABSTRACT | FULL TEXT  

Hyperinsulinemia and Cognitive Decline in a Middle-Aged Cohort
Young et al.
Diabetes Care 2006;29:2688-2693.
ABSTRACT | FULL TEXT  

Lp-PLA2: A New Kid on the Block
Zalewski et al.
Clin. Chem. 2006;52:1645-1650.
ABSTRACT | FULL TEXT  

Nontraditional CHD Risk Markers: How Much Value Do They Add?
Journal Watch Cardiology 2006;2006:1-1.
FULL TEXT  

C-Reactive Protein: Not Ready for Population-Wide CVD Risk Assessment
JWatch General 2006;2006:1-1.
FULL TEXT  

Predicting cardiovascular risk: so what do we do now?
Lloyd-Jones and Tian
Arch Intern Med 2006;166:1342-1344.
FULL TEXT